摘要
目的基于既往冠状病毒的研究,探索利巴韦林用于新型冠状病毒肺炎治疗的有效性和安全性。方法计算机检索PubMed、Web of Science、Embase、EBSCO、中国期刊全文数据库、维普、万方等数据库,检索有关利巴韦林用于SARS、MERS治疗有效性和安全性的队列研究以及案例报道,检索时间范围为2003年1月到2020年1月30日。结果有效性研究结果显示部分SARS和MERS患者使用利巴韦林后,病情得到控制和改善,治愈率和临床治疗结局也较好;安全性研究结果显示利巴韦林不良反应发生率较高,主要为贫血和心律失常,同时也有其他不良反应的报告。结论利巴韦林用于COVID-19治疗可能有效性,但还需进一步的临床实验来证实,同时由于不良反应发生率较高,临床使用前应仔细综合评估各项指标,排除存在用药禁忌证的患者,并在治疗过程中密切监测。
Objective To explore the efficacy and safety of ribavirin in novel coronavirus pneumonia based on previous coronavirus studies.Methods Systematically retrieve relevant clinical studies from Chinese and English databases such as CNKI,VIP,Wangfang Data,PubMed,Web of Science,Embase,EBSCO retrieving cohort studies and case reports on the efficacy of ribavirin in the treatment of SARS and MERS.The retrieval time range is from January 2003 to January 30,2020.Results The effectiveness study showed that some patients with SARS and MERS received ribavirin,the condition was controlled and improved,and the cure rate and clinical treatment outcome were also good.Safety studies have shown a high incidence of adverse reactions to ribavirin,mainly anemia and arrhythmia,and other adverse reactions have been reported.Conclusion Ribavirin may be effective in the treatment of COVID-19,but further clinical trials are needed to confirm it.At the same time,due to the high incidence of adverse reactions,all indicators should be carefully evaluated before clinical use and closely monitored during treatment.
作者
熊堉
蒋敏
边原
陈岷
童荣生
龙恩武
吴行伟
XIONG Yu;JIANG Min;BIAN Yuan;CHEN Min;TONG Rongsheng;LONG Enwu;WU Xingwei(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,China;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610072,China)
出处
《医药导报》
CAS
北大核心
2020年第4期498-504,共7页
Herald of Medicine
基金
国家临床重点专科建设资助项目(30305030698)
四川省省级公益性科研院所基本科研业务专项课题资助项目(2018YSKY0017)
四川省人民医院院级科研基金临床研究及转化资助项目(2018LY09)
四川省卫生健康委员会科研课题资助项目(19PJ269)。
